Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’

This article was originally published in The Pink Sheet Daily

Executive Summary

Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline:

You may also be interested in...

Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data

Aspen's Acquisition of Sigma For APAC Expansion Comes At Time Of Generics Uncertainty In Australia

TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division

GSK’s Strategy in Emerging Markets: Scale, Diversification and Access

Emerging markets present great opportunities, tempered by volatility, vastly different local environments, and ever-changing regulations.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts